홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Triphenylphosphine → 6-(4-(4-(aminomethyl)-4-methoxypiperidin-1-yl)furo[3,2-d]pyrimidin-2-ylamino)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one

HRID 1038810
노트
인쇄 미리보기

반응식

HRID 1038810 반응식
[N:1]([CH2:4][C:5]1([O:34][CH3:35])[CH2:10][CH2:9][N:8]([C:11]2[C:12]3[O:33][CH:32]=[CH:31][C:13]=3[N:14]=[C:15]([NH:17][C:18]3[CH:30]=[CH:29][C:21]4[O:22][C:23]([CH3:28])([CH3:27])[C:24](=[O:26])[NH:25][C:20]=4[CH:19]=3)[N:16]=2)[CH2:7][CH2:6]1)=[N+]=[N-].N(CC1(OC)CCN(C(OC(C)(C)C)=O)CC1)=[N+]=[N-].ClC1N=C(Cl)C2OC=CC=2N=1.NC1C=CC2OC(C)(C)C(=O)NC=2C=1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1>C1COCC1.O>[NH2:1][CH2:4][C:5]1([O:34][CH3:35])[CH2:6][CH2:7][N:8]([C:11]2[C:12]3[O:33][CH:32]=[CH:31][C:13]=3[N:14]=[C:15]([NH:17][C:18]3[CH:30]=[CH:29][C:21]4[O:22][C:23]([CH3:27])([CH3:28])[C:24](=[O:26])[NH:25][C:20]=4[CH:19]=3)[N:16]=2)[CH2:9][CH2:10]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

8

반응물 5

HCID 11776TriphenylphosphineHCID 136654966-Amino-2,2-dimethyl-2H-benzo[B][1,4]oxazin-3(4H)-oneHCID 457899682,4-Dichlorofuro[3,2-D]pyrimidineHCID 58504149Tert-butyl 4-(azidomethyl)-4-methoxypiperidine-1-carboxylateHCID 866650986-(4-(4-(azidomethyl)-4-methoxypiperidin-1-yl)furo[3,2-d]pyrimidin-2-ylamino)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one

생성물 1

HCID 687506336-(4-(4-(aminomethyl)-4-methoxypiperidin-1-yl)furo[3,2-d]pyrimidin-2-ylamino)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one수율 76%

시약·촉매·용매 2

HCID 962Water용매HCID 8028Tetrahydrofuran용매

실험 절차

A mixture of 6-(4-(4-(azidomethyl)-4-methoxypiperidin-1-yl)furo[3,2-d]pyrimidin-2-ylamino)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (0.030 g, 0.063 mmol, prepared using C from tert-butyl 4-(azidomethyl)-4-methoxypiperidine-1-carboxylate [WO 2010/080864, Example 257], A with 2,4-dichlorofuro[3,2-d]pyrimidine [ArkPharm] and B with 6-amino-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one [ArkPharm]) and triphenylphosphine (0.025 g, 0.094 mmol) in THF (16 mL) and water (2 mL) was stirred at about 100° C. overnight. The organic phase was removed and diluted with water. The aqueous phase was neutralized with aqueous 2 N NaOH and extracted with EtOAc. The combined organic phase was washed with brine and dried over Na2SO4, filtered, concentrated under vacuum and purified by HPLC (Table 2, Method v) to afford 6-(4-(4-(aminomethyl)-4-methoxypiperidin-1-yl)furo[3,2-d]pyrimidin-2-ylamino)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (0.022 g, 76%). LC/MS (Table 2, method h) Rt=1.77 min.; MS m/z: 453 (M+H)+. Syk IC50=A

후처리

  1. customprepared
  2. customThe organic phase was removed
  3. additiondiluted with water
  4. extractionextracted with EtOAc
  5. washThe combined organic phase was washed with brine
  6. dry with materialdried over Na2SO4
  7. filtrationfiltered
  8. concentrationconcentrated under vacuum
  9. custompurified by HPLC (Table 2, Method v)

출처 및 근거

ORD 기록
ord-85d6e2b468ea4ef6ad395896e46bcecf
출처 데이터셋
uspto-grants-2013_10
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08551981B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트